Annual Report Reveals Significant Increase in Net Loss and Cash Burn for FY2026

summarizeSummary

Cybin Inc.'s annual report shows a significant increase in net losses and cash burn for fiscal year 2026, underscoring its reliance on dilutive equity offerings to fund operations despite clinical trial progress.

check_boxKey Events · Corporate Governance and Compliance · HELP

• Net Loss Significantly Increased

  The company reported a net loss of $148 million for the fiscal year ended March 31, 2026, a substantial increase from $82 million in the prior year.

• High Cash Burn from Operations

  Net cash used in operating activities for FY2026 was $133 million, up from $72 million in FY2025, indicating a rapid rate of cash consumption.

• Substantial Dilutive Offering Completed

  A $50 million underwritten offering of 10,309,280 Common Shares was completed on June 25, 2026, increasing outstanding shares by approximately 20%.

• Ongoing Need for Financing

  The company expects continued losses and explicitly states it will require additional financing to fund its operations and development programs.

auto_awesomeAnalysis · HELP · Life Sciences

Cybin Inc.'s annual report reveals a substantial increase in net loss and cash burn for the fiscal year ended March 31, 2026, highlighting significant financial challenges despite ongoing clinical progress. The company's reliance on frequent, highly dilutive equity offerings to sustain operations, as evidenced by the recent $50 million raise and the explicit statement of future financing needs, indicates a precarious financial position. This level of cash consumption and dilution raises concerns about long-term shareholder value, even with positive clinical trial updates.